Document:

EX-10.11

 Exhibit 10.11 

EMPLOYMENT AGREEMENT 

EMPLOYMENT AGREEMENT (“Agreement”) made this May 6, 2010 between Dicerna Pharmaceuticals, Inc. (“Company’)
on the one hand and Douglas M. Fambrough, III (the “Executive”) on the other hand. 
 WHEREAS the Company desires to
employ the Executive and the Executive desires to be employed by the Company, on terms set forth herein; 
 NOW, THEREFORE, in
consideration of the mutual agreements set forth herein, the parties agree as follows: 
 1. Term of Employment. The Executive’s
employment under this Agreement shall commence on May 6, 2010 (the “Commencement Date”) and shall end on such date as the Executive’s employment terminates in accordance with Section 4 of this Agreement. Subject to the
balance of this Agreement, the Executive shall be an at-will employee of the Company whose employment may be terminated (by the Company or by the Executive) at any time, for any or no reason, in which case the Executive will be entitled to the
separation benefits set forth in Section 4, below. 
 2. Duties. 

a. Duties and Responsibilities. During his employment with the Company, the Executive shall have the title of President and Chief
Executive Officer of the Company. The Executive shall devote his full business time and effort to the performance of his duties for the Company, which he shall perform faithfully and to the best of his ability, provided that (i) it is
understood and agreed that the Executive will continue to serve in his role as a Venture Partner of Oxford Biosciences, (ii) the Executive may serve as a director on up to two (2) other boards of directors in his role as such a Venture
Partner (the Executive is presently on the board of directors of Xencor, Inc.), and (iii) the Executive may engage in charitable, religious, civic and educational activities and community affairs, provided that the activities described
in subsections (i), (ii) and (iii) above do not, alone or in the aggregate, materially interfere with the proper performance of the Executive’s duties and responsibilities to the Company. The Executive shall have all of the
customary powers and duties associated with his position and shall be subject to the Company’s policies, procedures, and approval practices, as generally in effect from time to time for all senior executives of the Company and the direction and
oversight of the Company’s Board of Directors (the “Board”). The Executive will report directly to the Board. 
 b. Board
Membership. The Executive shall serve as a member of the Board commencing on the Commencement Date, subject to any required approval of the Company’s shareholders. The Executive shall resign from the Board effective upon the termination of
the Executive’s employment with the Company for any reason (with the understanding that after such termination Oxford Biosciences may elect to have the Executive serve as a director of the Company as its designee). 

  
 1 

 EMPLOYMENT AGREEMENT 

 

 3. Compensation and Related Matters. 

a. Base Salary. The Company shall pay the Executive base salary at a rate of $14,423 every two weeks (which annualizes to $375,000),
less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives. 

b. Bonus. The Executive shall be eligible to be considered for a bonus upon achieving certain pre-determined performance targets to be
set by the Board for calendar year 2010 by the Commencement Date and within the first 90 days of each successive calendar year to which the targets relate and consistent with any incentive compensation plan established by the Board. The bonus shall
be based, in part, on the Executive’s performance. The grant of such a bonus shall be in the sole discretion of the Board. The target bonus amount for which the Executive will be eligible is thirty five percent (35%) of base salary earned
for the calendar year. Bonuses will be earned only after they have been granted by the Board. Any bonus shall be paid to the Executive following the close of the fiscal year to which it relates, in no event later than March 15th of the calendar year immediately following the calendar year in which it was earned. The Executive must be actively employed by the Company at the time the Board considers granting of bonuses to be
eligible to receive such bonus. 
 c. Stock/Stock Options. Subject to approval of the Board or an appropriate committee thereof, the
Company shall provide the Executive with the following: 
 i. Initial Option Grant. On the Commencement Date, the
Executive shall be granted an option (the “Initial Option”) to purchase 1,500,000 shares (the “Initial Option Shares”) of the Company’s common stock (the “Common Stock”), $.0001 par value per share, which shall
equal five percent (5%) of the outstanding shares of Common Stock of the Company as of the Commencement Date calculated on a fully diluted, as-converted basis. Twenty percent (20%) of the Initial Option Shares shall vest on the first
anniversary of the date of grant of the Initial Option, twenty percent (20%) of the Initial Option Shares shall vest in equal monthly installments thereafter over the subsequent twelve (12) months and the remaining sixty percent (60%)
shall vest in equal monthly installments thereafter over the subsequent twenty-four (24) months, subject to the Executive’s continued employment by the Company. The Initial Option shall be exercisable at a price per share equal to the fair
market value of the Common Stock of the Company on the date of grant. 
 ii. Additional Option Grant. Upon the
consummation by the Company of the first equity financing on and after the Commencement Date, whether consummated in a single transaction or through a series of related transactions, in which shares of preferred stock are issued by the Company
containing rights upon liquidation of the Company that are pari passu with or senior to the holders of the Company’s Series A Convertible Preferred Stock (the “Financing”), then, subject to Section 3.c.iii., the Executive
shall be granted an additional option (the “Additional Option”) to purchase that number of shares of Common Stock of the Company as shall equal five percent (5%) of the fully diluted shares or other securities (on an as-converted
basis) issued in connection with the Financing (the “Additional Option Shares”); provided that, in no event shall the number 

  
 2 

 EMPLOYMENT AGREEMENT 

 

 
of shares issuable in connection with the Additional Option exceed 1,500,000 shares (the “Additional Option Cap”). Twenty percent (20%) of the Additional Option Shares shall vest
on the first anniversary of the date of grant of the Additional Option, twenty percent (20%) of the Additional Option Shares shall vest in equal monthly installments thereafter over the subsequent twelve (12) months and the remaining sixty
percent (60%) shall vest in equal monthly installments thereafter over the subsequent twenty-four (24) months, subject to the Executive’s continued employment by the Company. The Additional Option shall be exercisable at a price per
share equal to the fair market value of the Common Stock of the Company on the date of grant. 
 iii. Incentive Option
Grant. Upon the achievement of certain objectives to be agreed in writing between the Executive and the Board, the Executive shall receive an additional option (the “Incentive Option”) to purchase 300,000 shares of Common Stock of the
Company plus a number of shares equal to one percent (1%) of the fully diluted shares issued in connection with the Financing (the “Incentive Option Shares”). This Incentive Option Grant shall be divided into two (2) equal
grants, each of which shall be contingent on the achievement of one or more of the mutually agreed upon objectives described above. Twenty percent (20%) of each grant of the Incentive Option Shares, as applicable, shall vest on the first
anniversary of the date of grant of such Incentive Option, twenty percent (20%) of each grant of the Additional Option Shares , as applicable, shall vest in equal monthly installments thereafter over the subsequent twelve (12) months and
the remaining sixty percent (60%) shall vest in equal monthly installments thereafter over the subsequent twenty-four (24) months, subject to the Executive’s continued employment by the Company. The Incentive Option shall be
exercisable at a price per share equal to the fair market value of the Common Stock of the Company on the date of grant. By way of example only, and without creating any right or obligation for either party, the type of objective that may trigger
the Incentive Option Grant, subject to the parties written agreement regarding the same, includes: completing the Financing at a price per preferred share that equals or exceeds one hundred ten percent (110%) of the price of a Company Series A
Convertible Preferred Share immediately following the Company’s most recent round of financing, closing a significant corporate collaboration within twelve (12) months following the Commencement date, or commencing a first-in-man clinical
trial of a dicer substrate by Q4 2011. 
 The Initial Option, the Additional Option and the Incentive Option shall be
subject to the terms and conditions as specified in the Company’s Third Amended and Restated 2007 Employee, Director and Consultant Stock Plan (the “Stock Plan”), and one or more non-qualified stock option agreements to be executed by
the Executive and the Company in substantially the form attached hereto as Exhibit A (the “Non-Qualified Stock Option Agreements”), one of which shall be executed by the Executive and the Company contemporaneously herewith. 

d. Benefits. During his employment, the Executive shall be entitled to participate in all employee benefit plans and programs,
including paid sick leave and holidays, life insurance, disability, medical, dental, and retirement savings plans, to the same extent generally available to senior executives of the Company, in accordance with the terms of those

  
 3 

 EMPLOYMENT AGREEMENT 

 

 
plans and programs. The Executive shall be permitted up to four (4) weeks of paid vacation per year, which will accrue on a monthly basis. The Executive will not be allowed to accumulate
more than four (4) weeks of unused vacation days at any given time. The Executive may carry over a maximum of five unused vacation days from one calendar year to the next. 

e. Expenses. 

i. Business Expenses. The Company agrees to reimburse the Executive for reasonable out-of-pocket expenses incurred in
connection with Company business and within standards to be established by the Board from time to time, including, without limitation, travel and accommodations for authorized business trips, provided that vouchers therefore, or other
supporting information as the Company may reasonably require, are presented to the Company. 
 ii. Reimbursement
Requirements. The Executive must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. Any reimbursement (or right thereto) may not be exchanged or liquidated for
another benefit or payment. Any business expense reimbursements subject to Section 409A of the Code and the rules and regulations thereunder (“Section 409A”) shall be made no later than the end of the calendar year following the
calendar year in which such business expense is incurred by the Executive, and the expenses eligible for reimbursement in any tax year will not affect the expenses eligible for reimbursement in any other tax year. 

f. Attorneys’ Fees. The Company agrees to reimburse the Executive for documented and appropriate attorneys’ fees paid by the
Executive in connection with the negotiation and execution of this Agreement, up to a maximum total amount of ten thousand dollars ($10,000). 

g. Indemnification; Liability Insurance. The Company agrees to indemnify and hold harmless the Executive for the Executive’s
conduct as an officer, director and employee of the Company and to provide the Executive with directors’ and officers’ liability insurance coverage, to the extent that the Company provides such aforementioned indemnification right and
liability insurance coverage to similarly situated officers and directors of the Company. 
 4. Termination. 

a. Rights and Duties. The Executive is an employee “at will.” Accordingly, the Company or the Executive may terminate his
employment, at any time for any lawful reason, or no reason. The Executive and the Company agree that, without modifying or altering the Executive’s “at will” status each will provide the other with at least thirty (30)
days’ prior written notice of termination of the Executive’s employment with the Company. If the Executive gives notice of termination, except in the case of a termination by the Executive for “Good Reason” as set forth below,
such notice will be deemed a voluntary resignation by the Executive and the Company, in its sole discretion, may elect to relieve the Executive of any obligation to perform duties during the notice period, without changing the status of such

  
 4 

 EMPLOYMENT AGREEMENT 

 

 
termination as a voluntary resignation by the Executive. Should the Company in the event of a voluntary resignation decide to relieve the Executive of any obligation to perform duties during the
notice period, it shall nonetheless continue his compensation and benefits for the term of the notice period, except that no bonus shall be earned or awarded during and after the notice period. 

b. Termination for “Good Reason.” The Executive may terminate his employment at any time for “Good Reason.”
“Good Reason” shall mean: 
 i. A material diminution in the Executive’s authority, duties or
responsibilities, or a requirement that he be required to report to an officer or employee rather than to the Board; 
 ii. A
material diminution by the Company in the Executive’s annual base compensation then in effect, except those changes generally affecting the members of the Company’s management; 

iii. An action or inaction by the Company that constitutes a material breach by the Company of the terms of this Agreement. If
such breach is reasonably possible of being cured in the opinion of the Company, then the Company will be given thirty (30) days after written notice from the Executive of such breach to cure. 

iv. A requirement that the Executive be based more than fifty (50) miles from the offices at which he was principally
employed immediately prior to the date of termination. 
 The parties acknowledge and agree that “Good Reason” shall not be deemed
to have occurred unless: (1) the Executive provides the Company with written notice that he intends to terminate his employment hereunder for one of the Good Reason grounds set forth in Section 4.b. within sixty (60) days of the
initial occurrence of such ground, with such notice containing a description of such ground, (2) if such Good Reason ground is capable of being cured, the Company has failed to cure such ground within a period of thirty (30) days from the
date of such written notice, and (3) the Executive terminates his employment within one hundred twenty (120) days from the date that such Good Reason ground first occurs. For purposes of clarification, the above-listed conditions shall
apply separately to each occurrence of a Good Reason ground, and failure to adhere to such conditions in the event of the occurrence of grounds that would otherwise have constituted Good Reason had the conditions herein been satisfied shall not
disqualify the Executive from asserting and satisfying the conditions for Good Reason for any subsequent occurrence that may constitute Good Reason. 

c. Termination by the Company for Cause. The Company may terminate the Executive’s employment at any time for “Cause.”
“Cause” shall mean: 
 i. Executive’s commission of an act of fraud or dishonesty which may or does adversely
affect the Company; 
 ii. The Executive’s conviction or plea of guilty or nolo contendere to or engaging in any
felony or crime involving moral turpitude, fraud, misrepresentation or other crime and/or indictment for a crime that, in the reasonable opinion of the Company, affects the Executive’s ability to perform the duties set forth in this Agreement
and/or reflects negatively upon the Company; 

  
 5 

 EMPLOYMENT AGREEMENT 

 

 iii. Unauthorized disclosure by the Executive of the Company’s
Proprietary Information, as defined in the Nondisclosure, Noncompetition and Assignment Agreement which results or could have been reasonably foreseen to result, in a material financial loss to the Company; or 

iv. The Executive’s failure (which shall not include any Disability as defined below) or refusal to perform the duties and
responsibilities of his employment and/or to follow the policies and procedures of the Company, including without limitation the failure or refusal to carry out lawful instructions from the Board. If such failure or refusal is reasonably possible of
being cured in the opinion of the Company, then the Executive will be given thirty (30) days after written notice from the Company of such failure or refusal to cure. 

d. Termination in the Event of Death or Disability. The Agreement shall terminate upon the Executive’s death or Disability. For
purposes of the Agreement, “Disability” is defined as any illness, injury, accident or condition of either a physical or psychological nature as a result of which the Executive is unable to perform the essential functions of his duties and
responsibilities hereunder for ninety (90) days during any period of three hundred sixty five (365) consecutive calendar days or for any consecutive ninety (90) day period. 

e. Effect of Termination. 

i. If the Executive is terminated by the Company for Cause, the Executive will only be entitled to payment when due of any
unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment. In addition, the Executive may exercise any vested but unexercised options under Section 4.c. within three (3) months after the date
the Executive ceases to be an employee of the Company or within the originally prescribed term of the applicable option, whichever is earlier (but not thereafter). 

ii. If the Executive is terminated by the Company other than for Cause or due to the Executive’s Disability, as defined
above (either of which will be deemed an involuntary termination), or the Executive terminates for Good Reason, the Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days accrued prior to
termination of employment and, in exchange for the Executive’s execution of a separation agreement and general release provided by the Company, which must be executed by the Executive and returned to the Company within the applicable Execution
Period (the Execution Period shall be the thirty (30) day period beginning on the date of Executive’s termination of employment, or, if necessary in order to comply with applicable legal requirements for releases under the Older Workers
Benefit Protection Act or related employment law, as determined by the Company in its sole discretion, the sixty (60) day period beginning on the date of the Executive’s termination of employment), the following: 

a) Continuation of the Executive’s base salary at the rate in effect as of the day immediately preceding his date of
termination for twelve (12) months following the date of termination, payable in accordance with the Company’s regular payroll practices, with such payment to commence on the Company’s next regularly scheduled payroll following the 10th day after the expiration of the applicable Execution Period in which the Executive provides to the Company the executed separation agreement and general release described above; provided,
however that the first installment shall include all amounts which would have been paid during the period between the Executive’s date of termination and the date of such first installment and provided, further, that each installment shall be
considered a separate payment for purposes of Section 409A of the Code. 

  
 6 

 EMPLOYMENT AGREEMENT 

 

 b) The Executive shall be eligible to continue health benefits pursuant to
COBRA or the appropriate state equivalent. If the Executive is eligible for and properly elects continuation of such coverage during the required timeframe, the Company will pay the premiums for such group health insurance coverage for the shorter
of: (i) twelve (12) months or (ii) until the Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of
such group health insurance coverage, pursuant to the terms and conditions of COBRA. 
 c) Payment of a pro-rata portion of
the target amount of the Executive’s annual bonus, with such pro-rata portion calculated by multiplying the maximum potential amount of such bonus for the year in which such termination occurs (pursuant to Section 3.b. of this Agreement,
i.e., 35% of the Executive’s base salary as of the date of termination) by a number: (x) the numerator of which is the number of days worked by the Executive during the fiscal year prior to termination, and (y) the
denominator of which is three hundred sixty five (365), with such payment to be made on the Company’s next regularly scheduled payroll following the 10th day after the expiration of the
applicable Execution Period in which the Executive provides to the Company the executed separation agreement and general release described above. 

iii. For clarity, in the event of a termination by the Executive for Good Reason, the Executive shall be entitled to the
separation compensation and benefits set forth in Section 4.e.ii. of this Agreement. 
 iv. If the Agreement is
terminated because of the Executive’s death, the Company shall pay to the estate of the Executive the salary and benefits which would otherwise have been payable to the Executive up to the date of termination of his employment because of death.

 v. In the event that a Change of Control (as defined below) occurs and, if within one (1) year thereafter, the
Executive’s employment is terminated as an involuntary termination by the Company for a reason other than for Cause, or by the Executive for Good Reason, then, in addition to providing the payments and benefits

  
 7 

 EMPLOYMENT AGREEMENT 

 

 
described in Section 4.e.ii. of this Agreement, the Company shall accelerate the vesting of one hundred percent (100%) of any unvested Initial Option Shares, Additional Option Shares or
Incentive Option Shares granted to the Executive under Section 3.c. of this Agreement pursuant to the terms and conditions of the Stock Plan and/or any applicable Stock Agreements. The provision of payments and benefits under this
paragraph (beyond payment of any unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment) also are subject to the Executive’s execution of a separation agreement and general release provided
by the Company within the time period set forth in Section 4.e.ii.(a) and (c) above. The terms and conditions of any applicable Stock Agreements shall so provide for such acceleration. 

For purposes of this Agreement, “Change of Control” means the occurrence of a merger or consolidation of the Company
whether or not approved by the Board of Directors, other than: (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving
entity or parent of such corporation outstanding immediately after such merger or consolidation, or a merger or consolidation which is in effect a financing transaction for the Company, including, but not limited to, a reverse merger of the Company
into a publicly traded “shell” company, or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 

5. Nondisclosure, Noncompetition, Nonsolicitation and Inventions. As a condition of the Executive’s employment by the Company and
the payment of compensation and receipt of benefits referred to above, the Executive agrees to execute the attached standard Nondisclosure, Noncompetition and Assignment Agreement, in the form attached hereto as Exhibit B. The Executive
acknowledges that the Company would not offer him employment or provide compensation and/or benefits set forth above if he was not willing to be bound by the terms of such Agreement. 

6. Certifications to the Company. By signing this Agreement, the Executive is certifying and representing to the Company that:
(a) he is free to enter into and fully perform the duties of his position as an employee or director of the Company; (b) he is not subject to any employment, confidentiality, non-competition or other agreement that would restrict his right
to work for or serve on the Board of the Company in any way, and he has provided the Company with a copy of any agreement that could be interpreted as restricting his right to work for the Company in any way; (c) his employment and Board
membership with the Company does not violate any order, judgment or injunction applicable to him, and he has provided the Company with a copy of any such order, judgment or injunction which may be applicable to him; and (d) all facts he has
presented to the Company are accurate and true, including oral and written statements regarding his education, training, qualifications, and prior work experience. 

  
 8 

 EMPLOYMENT AGREEMENT 

 

 7. Notice. 

a. To the Company. The Executive will send all communications to the Company in writing, addressed as follows (or in any other manner
the Company notifies him to use): 
 David Madden 

Chairman of the Board of Directors 

Dicerna Pharmaceuticals, Inc. 

480 Arsenal Street, Building 1, Suite 120 

Watertown, MA 02472 
 Phone:
(617) 621-8097 
 Fax:
                     
 With a copy to:

 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

One Financial Center 
 Boston,
MA 02111 
 Attention: John J. Cheney, Esq. 

Phone: (617) 542-6000 

Fax: (617) 542-2241 
 b.
To the Executive. All communications from the Company to the Executive relating to this Agreement shall be sent to the Executive in writing, addressed as follows (or in any other manner he notifies the Company to use): 

Douglas M. Fambrough, III 
 23
Holyoke Street #1 
 Boston, MA 02116 

Phone: (617) 266-7712 

Fax:                      

With a copy to: 

Goodwin|Procter LLP 
 Exchange
Place 
 Boston, MA 02109 

Attention: Kingsley L. Taft, Esq. 

Phone: (617) 570-1222 

Fax: (617) 570-1222 
 c.
Time Notice Deemed Given. Notice shall be deemed to have been given when delivered or, if earlier (1) three business days after mailing by United States certified or registered mail, return receipt requested, postage prepaid, or
(2) faxed with confirmation of delivery, in either case, addressed as required in this section. 

  
 9 

 EMPLOYMENT AGREEMENT 

 

 8. Amendment. No provisions of this Agreement may be modified, waived, or discharged
except by a written document signed by a Company officer duly authorized by the Board and the Executive. A waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at
any other time in the future. 
 9. Choice of Law; Forum Selection. The validity, interpretation, construction, and
performance of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to its conflicts of laws principles. Any claims or legal actions by one party against the other regarding this Agreement shall be
commenced and maintained in any state or federal court located in the Commonwealth of Massachusetts, and the parties hereby submit to the jurisdiction and venue of any such court. 

10. Successors. This Agreement shall be binding upon, and shall inure to the benefit of, the Executive and his estate, but the
Executive may not assign or pledge this Agreement or any rights arising under it. Without the Executive’s consent, the Company may assign this Agreement to any affiliate or to a successor to substantially all the business and assets of the
Company. 
 11. Taxes; Section 409A. 

a. The Company shall withhold taxes from payments it makes pursuant to this Agreement as it reasonably determines to be required by
applicable law. 
 b. If any of the benefits set forth in this Agreement are “deferred compensation” subject to
Section 409A, any termination of employment triggering payment of such benefits must constitute a “separation from service” under Section 409A before a distribution of such benefits can commence. For purposes of clarification,
this section shall not cause any forfeiture of benefits on the part of the Executive, but shall only act as a delay until such time as a “separation from service” occurs. In addition, if any amount to be paid to the Executive pursuant to
this Agreement as a result of the Executive’s separation from service is “deferred compensation” subject to Section 409A, and if the Executive is a “Specified Employee” (as defined under Section 409A) as of the
date of the Executive’s separation from service hereunder, then, to the extent necessary to avoid the imposition of accelerated or increased income taxes, excise taxes or other penalties under Section 409A, the payment of benefits, if any,
scheduled to be paid by Company to the Executive hereunder during the first six (6) month period following the date of a separation from service hereunder shall not be paid until the date which is the first business day after
six (6) months have elapsed since Executive’s separation from service or such earlier time as may be permitted under Section 409A of the Code. Any deferred compensation payments delayed in accordance with the terms of this
Section 11 shall be paid in a lump sum when paid and shall be adjusted for earnings in accordance with the applicable short term rate under Section 1274(d) of the Code. 

c. Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be interpreted and at all times
administered in a manner that avoids the inclusion of compensation in income under Section 409A, or the payment of increased taxes, excise taxes or other penalties under Section 409A. 

  
 10 

 EMPLOYMENT AGREEMENT 

 

 d. The parties intend this Agreement to be in compliance with Section 409A.
However, the Executive acknowledges and agrees that Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to
Section 409A. 
 12. Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 
 13.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument. 

14. Entire Agreement; Prior Agreements. This Agreement, together with any other agreement described in this Agreement, constitutes the
entire agreement among the parties with respect to the subject matter hereof and, unless otherwise provided herein, supersedes all prior agreements or understandings written or oral in respect thereof. 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as a sealed instrument as of the date first written above. 

 

							
		 		 	DICERNA PHARMACEUTICALS, INC.
			
	Date:             , 2010	 		 	 /s/ David M. Madden

		 		 	By:	 	D. Madden
				
		 		 	Its:	 	Chairman
			
		 		 	Douglas M. Fambrough, III
			
	Date: May 6, 2010	 		 	 /s/ Douglas M. Fambrough, III

  
 11 

 EXHIBIT A 

[Non-Qualified Stock Option Agreement] 

  
 1 

 EXHIBIT B 

NONDISCLOSURE, NONCOMPETITION AND ASSIGNMENT AGREEMENT 

This Nondisclosure, Noncompetition and Assignment Agreement (the “Agreement”) is made by and between Dicerna Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and Douglas M. Fambrough, III (the “Employee”), as of May 6 , 2010. 

The Employee acknowledges that his employment or the continuance of that employment with the Company is contingent upon his agreement to sign
and adhere to the provisions of this Agreement. In consideration of the employment or continued employment of the Employee by the Company, the Employee and the Company agree as follows: 

1. Duty to Devote Efforts. The Employee hereby reconfirms his obligations under Section 2(a) of his Employment Agreement with the
Company (as such agreement may be amended or restated in the future, the “Employment Agreement”). 
 2. Noncompetition. The
Employee recognizes and agrees that the Company will suffer irreparable harm in the event that the Employee enters into competition with the Company, either during or following the Employee’s employment with the Company. Therefore, the Employee
agrees that while the Employee is employed by the Company and for a period of one (1) year following the termination or cessation of such employment (the “Restricted Period”), regardless of the reasons, the Employee shall not,
directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity, (a) accept employment with any business or entity that is in
competition with the products or services being conceived, designed, created, developed, manufactured, marketed, distributed or sold by the Company, (b) engage in or undertake any business operations of conceiving, designing, creating,
developing, manufacturing, marketing, distributing selling or rendering (or assisting any other person in conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering) products or services that are in
competition with the products or services being conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company or (c) invest in or assist in any manner any business which directly or indirectly
competes with the business or future business plans of the Company, except that he may own up to one percent (1%) of the outstanding securities of any corporation having a class of equity securities actively traded on a national securities
exchange or on the NASDAQ Stock Market. For purposes of clauses (a) to (c) above, which are hereby so limited, a business or entity and a products or service shall be deemed to be in competition with the products or services being
conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company if it is in the business of development, manufacture, license, sale and distribution of Dicer-substrate based therapeutic and diagnostic
products (including, but not limited to, Dicector RNA interference technology and DsiRNA technology). For clarity, the Employee will not be in violation of this Section 2 or Sections 3 or 4 based on his role as a venture investor and director,
provided that the Employee is not individually and personally involved in activities prohibited by those Sections. The geographic scope of this Section 2 shall extend to anywhere the Company is doing business, has done business or intends to do
business. The Employee acknowledges and agrees that if he violates any of the provisions of this Section 2, the running of the Restricted Period will be extended by the time during which he engages in such violation(s). 

  
 1 

 3. Nonsolicitation of Customers. The Employee recognizes and agrees that the clients,
customers and accounts of the Company, which the Company now or hereafter services during the Employee’s employment with the Company, and all prospective clients, customers and accounts from whom the Employee has solicited business while in the
employ of the Company, shall be solely the clients, customers and accounts of the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of one (1) year following the termination or cessation
of such employment, regardless of the reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity,
solicit for the purposes of “competition” with the Company (as described in Section 2 above), divert or take away, attempt to divert or to take away, any client, customer or account of the Company, or any potential client, customer or
account of the Company which were contacted, solicited or served by the Employee while employed by the Company or about whom the Employee obtained or became familiar with through Confidential Information (as defined in Section 5). The
geographic scope of this Section 3 shall extend to anywhere the Company is doing business, has done business or intends to do business. 

4. Nonsolicitation of Employees. The Employee recognizes and agrees that the Company has invested substantial resources and effort in
assembling its present staff and personnel. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of one (1) year following the termination or cessation of such employment, regardless of the reasons,
the Employee shall not, directly or indirectly: (i) recruit, solicit or hire any current employee of the Company or former employee of the Company whose employment with the Company terminated (for any reason) within six (6) months prior to
such recruitment, solicitation or hiring; or (ii) induce or attempt to induce any employee of the Company to terminate his employment with, or otherwise cease his relationship or engagement with, the Company. 

5. Nondisclosure. The Employee agrees that all Confidential Information (as defined below), whether or not disclosed orally or in
writing, is and shall be the exclusive property of the Company. The Employee shall not at any time, whether during or after the termination or cessation of his employment, without written authorization of the Company’s Board of Directors, and
unless and until the Confidential Information has become public knowledge without fault by the Employee, (a) reveal any Confidential Information to any person or entity, except to employees, consultants or business partners of the Company who
need to know such Confidential Information for the purposes of their employment or business relationship and are under a similar contractual obligation to keep such information confidential, (b) use or attempt to use any Confidential
Information for any purposes, other than in the ordinary course of performing his duties as an employee of the Company, or (c) use any Confidential Information in any manner which may injure or cause loss or may be calculated to injure or cause
loss to the Company, whether directly or indirectly. The term “Confidential Information” shall include any information concerning the organization, business, business relationships or finances of the Company or of any third party which the
Company is under an obligation to keep confidential or that is maintained by the Company as confidential. Such 

  
 2 

 
Confidential Information shall include, but is not limited to, trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems,
processes, specifications, blueprints, engineering data, software programs, works of authorship, clinical testing programs, marketing material, customer lists, customer information, financial information, pricing information, personnel information,
business plans or strategy, projects, plans and proposals. 
 6. Company Property. 

a. The Employee agrees that Company Property (as defined below) shall be and is the exclusive property of the Company to be used by the
Employee only in the performance of his duties for the Company and further agrees that during his employment with the Company, or after the termination or cessation of such employment, he shall not make, use or permit to be used any Company Property
otherwise than for the benefit of the Company. All such Company Property or copies thereof and all tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i) a
request by the Company or (ii) upon the termination or cessation of the Employee’s employment. After such delivery, the Employee shall not retain any such Company Property or copies thereof or any other tangible property. The term
“Company Property” shall include all files, letters, notes, memoranda, reports, lists, records, drawings, sketches, laboratory notebooks, specifications, software programs, software code, data, computers, cellular telephones, pagers,
credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any form, whether written, photographic, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the
business of the Company or concerning any of its dealings or affairs and any other Company property in Employee’s possession, custody or control. 

b. The Employee agrees that his obligation not to disclose or to use information and materials of the types set forth in Section 6(a)
above, and his obligation to return materials and tangible property, set forth in Section 6(a) above, also extends to such types of information, materials and tangible property of clients, customers and accounts of the Company or suppliers to
the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee. 
 7. Assignment of
Developments. 
 a. If at any time or times during the Employee’s employment with the Company, or prior to the Employee’s
employment with the Company when working with, for, or on behalf of the Company in a capacity other than as a Venture Partner of Oxford Biosciences, he did or shall (either alone or with others) make, conceive, create, discover, invent or reduce to
practice, whether or not during normal working hours or on the premises of the Company, any Development that (i) relates to the business of the Company or any customer of or supplier to the Company or any of the products or services being
developed, manufactured or sold by the Company or which may be used in relation therewith; (ii) results from tasks assigned to the Employee by the Company; or (iii) results from the use of premises or personal property (whether tangible or
intangible) owned, leased or contracted for or by the Company (other than de minimis use of a personal computer and other office equipment), then all such Developments 

  
 3 

 
and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. The term “Development”
shall mean any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any
interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes). The Employee shall fully and promptly disclose to the Company (or any persons designated by it) each such Development. To the extent not
already owned by the Company, the Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his right, title and interest (including, but not limited to, rights to inventions, patentable
subject matter, copyrights and trademarks) in and to the Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing
to others the same, all available information relating thereto (with all necessary plans and models) to the Company. The Employee also hereby waives all claims to moral rights in any Developments. 

b. Excluded Developments. This Section 7 shall not apply to Developments which do not relate to the present or planned business or
research and development of the Company and which are made and conceived by the Employee not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Confidential Information, but
shall apply to Developments made prior to the Employee’s employment as an employee, as described and as limited in the first sentence of section 7.a. above. The Employee represents that the Developments identified in the Appendix, if any,
attached hereto comprise the complete list of all the Developments that the Employee has made or conceived or otherwise claimed ownership prior to his employment by the Company, as described and as limited in the first sentence of section 7.a.
above, which Developments are excluded from this Agreement, the Employee understands that it is only necessary to list the title of such Developments and the purpose thereof but not details of the Development itself. IF THERE ARE ANY SUCH
DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. 
 8.
Further Assurances. The Employee agrees to cooperate fully with the Company, both during and after his employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual
property rights (both in the United States and foreign countries) relating to Developments. The Employee shall, during his employment and at any time thereafter, at the request and cost of the Company, promptly sign, execute, make and do all such
deeds, documents, acts and things as the Company and its duly authorized officers may reasonably require: 
 a. to apply for, obtain,
register and vest in the name of the Company alone (unless the Company otherwise directs) patents, copyrights, trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to
renew and restore the same; and 

  
 4 

 b. to defend any judicial, opposition or other proceedings in respect of such applications and
any judicial, opposition or other proceeding, petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 

The Employee further agrees that if the Company is unable, after reasonable effort, to secure the Employee’s signature on any such
papers, application for patent, copyright, trademark or other analogous protection, or other documents regarding any legal protection relating to a Development, whether because of the Employee’s physical or mental incapacity or for any other
reason whatsoever, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee’s agent and attorney-in-fact, to act for and on his behalf and stead to execute and file any such
papers, application or applications or other documents and to do any and all other lawfully permitted acts to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same
legal force and effect as if executed by the Employee. 
 9. Employment At Will. The Employee understands that this Agreement does
not constitute an implied or written employment contract and that his employment with the Company is on an “at-will” basis. Accordingly, the Employee understands that either the Company or the Employee may terminate Employee’s
employment at any time, for any or no reason, with or without prior notice. 
 10. Severability. The Employee hereby agrees that each
provision and the subparts of each provision herein shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if
one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the
appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. The Employee hereby further agrees that the language of all parts of this
Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either of the parties. 

11. Amendments; Waiver. Any amendment to or modification of this Agreement, or any waiver of any provision hereof, shall be in writing
and signed by the Company. No delay or omission by the Company in exercising any right under this Agreement or any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of that right or
any subsequent breach of such provision or any other provision hereof 
 12. Survival. This Agreement shall be effective as of the
date entered below. The Employee’s obligations under this Agreement shall survive the termination or cessation of his employment regardless of the manner of such termination or cessation and shall be binding upon his heirs, executors,
administrators and legal representatives. 
 13. Assignment. The term “Company” shall include Dicerna Pharmaceuticals, Inc.
and any of its subsidiaries, divisions, or affiliates. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said
successors or assigns. The Employee may not assign this Agreement. 

  
 5 

 14. Representations. 

a. The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms
of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his employment with the Company or to refrain from competing, directly or
indirectly, with the business of such previous employer or any other party. The Employee further represents that his performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep
in confidence proprietary information, knowledge or data acquired by the Employee in confidence or in trust prior to his employment with the Company, and the Employee will not disclose to the Company or induce the Company to use any confidential or
proprietary information or material belonging to any previous employer or others. The Employee further represents that he has returned all property and confidential information belonging to all prior employers. To the extent that Employee has
retained any non-confidential and nonproprietary materials and documents of a prior employer, such materials and documents have been disclosed in writing to the Company. 

b. The Employee hereby represents that his employment with the Company, the execution of this Agreement and his performance of all of the
terms of this Agreement do not and will not conflict with or breach the terms of any other agreement by which the Employee is bound (including, but not limited to, to keeping in confidence proprietary information acquired by the Employee in
confidence or in trust prior to his employment by the Company). The Employee further represents that he shall not enter into any agreement, either written or oral, in conflict herewith. 

c. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are
considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement by him is likely to cause substantial and irreparable damage to the Company and that in the event of such breach the Company shall
have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation of the Employee’s obligations hereunder. The Company may apply for such injunctive relief in
any court of competent jurisdiction without the necessity of posting any bond or other security. 
 15. Governing Law: Forum Selection
Clause. This Agreement and any claims arising out of this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts,
without application of the conflict of laws principles thereof. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or federal court located in the Commonwealth of Massachusetts, and the parties
hereby submit to the jurisdiction and venue of any such court. 

  
 6 

 16. Entire Agreement. This Agreement sets forth the complete, sole and entire agreement
between the parties on the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into, discussed or considered by the parties. The
Employee agrees that any change or changes in his duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

THE EMPLOYEE ACKNOWLEDGES THAT HE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as a sealed instrument as of the date first written above.

  

							
		 		 	DICERNA PHARMACEUTICALS, INC.
			
	Date:             , 2010	 		 	 /s/ David Madden

		 		 	By:	 	David Madden
				
		 		 	Its:	 	Chairman
			
		 		 	Douglas M. Fambrough, III
			
	Date: May 6, 2010	 		 	 /s/ Douglas M. Fambrough, III

  
 7EX-10.12

 Exhibit 10.12 

EXECUTION COPY 
 EMPLOYMENT
AGREEMENT 
 EMPLOYMENT AGREEMENT (“Agreement”) made this 1st day of May, 2008 between Dicerna Pharmaceuticals, Inc.
(“Company”) on the one hand and Bob D. Brown (the “Executive”) on the other hand. 
 WHEREAS the Company desires to
employ the Executive and the Executive desires to be employed by the Company, on terms set forth herein; 
 NOW, THEREFORE, in consideration
of the mutual agreements set forth herein, the parties agree as follows: 
 1. Term of Employment. The Executive’s
employment under this Agreement shall commence on May 5, 2008 and shall end on such date as the Executive’s employment terminates in accordance with Section 4 of this Agreement. Subject to the balance of this Agreement, the Executive
shall be an at-will employee of the Company whose employment may be terminated (by the Company or by the Executive) at any time, for any or no reason, in which case the Executive will be entitled to the separation benefits set forth in
Section 4, below. 
 2. Duties. During his employment with the Company, the Executive shall have the title of
Senior Vice President of Research. The Executive shall devote his full business time and effort to the performance of his duties for the Company, which he shall perform faithfully and to the best of his ability, provided, however, that the Executive
shall be permitted to serve on one Board of Directors or scientific advisory board only (whether for-profit or not-for-profit) that is approved in advance by the Company’s Board of Directors, such approval which shall not be unreasonably
withheld, as long as such activities do not interfere with the Executive’s duties under this Agreement . The Executive shall have all of the customary powers and duties associated with his position and shall be subject to the Company’s
policies, procedures, and approval practices, as generally in effect from time to time for all senior executives of the Company and the direction and oversight of the Company’s Board of Directors (the “Board”). The Executive will
report directly to the President and CEO of the Company. 
 3. Compensation and Related Matters. 

a. Base Salary. The Company shall pay the Executive base salary at a rate of $10,416.67 paid twice monthly (which annualizes to
$250,000), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives.

 b. Signing Bonus. The Company shall pay the Executive a one-time signing bonus of $50,000, less applicable withholdings,
within the first fifteen (15) days of the Executive’s employment with the Company. The signing bonus is subject to the following repayment obligation: As a condition of the Executive’s employment with the Company and for receiving the
Signing Bonus, the Executive agrees that if, at any time during the twelve months following his first date of employment with the Company, the Executive (a) resigns his employment with the Company for any reason other than as provided for in
Section 4.b. and/or Section 4.e.v. below, the Executive shall repay the Signing Bonus, less applicable withholdings deducted, to 

  
 1 

 
the Company on a pro-rated basis based on length of service; or (b) the Company terminates his employment for Cause (as defined below), the Executive shall repay the Signing Bonus, less
applicable withholdings deducted, to the Company, and in all cases specifically authorizes the Company to deduct all of the Signing Bonus required to be repaid under this Agreement from his last paycheck and to the extent that there is a balance
still owed by the Executive, the Executive will provide payment of such balance within thirty days (30) of his last date of employment. The Executive will not be deemed to have earned the Signing Bonus if, for any reason, the Executive is not
employed by the Company or if the Executive has given notice of termination or been notified of his termination at the time such Signing Bonus is to be paid. 

c. Annual Bonus. The Executive shall be eligible to be considered for an Annual Bonus upon achieving of certain pre-determined
performance targets to be set by the Board and consistent with any Incentive Compensation Plan established by the Board to the same extent generally available to senior executives of the Company. The Annual Bonus shall be based, in part, on the
Executive’s performance. The grant of such a bonus shall be in the sole discretion of the Board. The maximum bonus amount for which the Executive will be eligible is thirty percent (30%) of base salary earned for the calendar year. Bonuses
will be earned only after they have been granted by the Company’s Board of Directors. The Executive must be actively employed by the Company at the time the Board considers granting of bonuses to be eligible to receive such bonus. 

d. Stock Options. The Executive will receive, pursuant to the Second Amended and Restated 2007 Employee, Director and Consultant
Stock Plan (the “Plan”), an incentive stock option (ISO), dated the date the Executive commences employment, to purchase up to 300,000 shares of Common Stock at an exercise price equal to the Fair Market Value of each share on the date of
grant. The ISO will vest 25% after one year and then 1/36 at the end of each of the next 36 months. The ISO will fully accelerate upon a Change in Control of the Company, as defined in the Plan 

e. Benefits. During his employment, the Executive shall be entitled to participate in all employee benefit plans and programs,
including paid sick leave and holidays, life insurance, disability, medical, dental, and retirement savings plans, to the same extent generally available to senior executives of the Company, in accordance with the terms of those plans and programs.
The Executive shall be permitted up to four weeks of paid vacation per year. 
 f. Expenses. The Company agrees to
reimburse the Executive for reasonable out-of-pocket expenses incurred in connection with Company business and within standards to be established by the Board from time to time, including, without limitation, travel and accommodations for authorized
business trips, provided vouchers therefore, or other supporting information as the Company may reasonably require, are presented to the Company (“qualified expenses”). Reimbursements for such “qualified expenses” shall be made
no later than March 15 of the calendar year following the year in which such expenses were incurred. 
 g. Relocation and
Moving Expenses. 
 i. Temporary Accommodations. The Company agrees to reimburse the Executive for (a) the
work-related traveling between Millington, New Jersey and Boston, 

  
 2 

 
and (b) for the temporary accommodations for the Executive up to $4,500 per month (or a figure agreed upon between the Executive and the Company for a fair standard of living accommodation)
until the earlier of (a) the move of his family to the Boston, Massachusetts area from Millington, New Jersey or (b) October 14, 2008, subject to later date as may be mutually agreed to by the parties. 

ii. Relocation and moving. The Company also agrees to reimburse the Executive: 

(A) up to an aggregate of $50,000, without prior approval from the Company, for closing costs (including brokers’ fees but
excluding points) in connection with the sale of his house in Millington, New Jersey and the purchase of a house in the Boston, Massachusetts area; and 

(B) expenses related to up to three (3) house hunting trips (such trips which may include the Executive’s immediate
family), automobile transportation fees, airline tickets from Millington, New Jersey to Boston for the Executive and his immediate family, and related moving and relocation expenses (other than those provided for in Section 3(g)(ii)(A) above),
for the Executive and his immediate family’s move to the Boston, Massachusetts area. 
 iii. The reimbursement of
Relocation Expenses and other expenses set forth in this Sections 3.g.(i) and 3.g.(ii) will be grossed up for taxes, to the extent they are taxable as income to the Executive in accordance with the applicable sections of the Internal Revenue Code.

 iv. Reimbursement in case of early termination. The amounts set forth in Sections 3.g.(i), 3.g.(ii) and 3(g)(iii) above
are hereinafter collectively referred to as the “Relocation Expenses”. The Executive will reimburse the Company for 50% of Relocation Expenses received by the Executive from the Company if the Executive voluntarily resigns his employment
from the Company at any time during the 6 month period immediately following the date the Executive commences employment, unless such resignation is for “Good Reason” (as defined below). 

v. All Relocation Expenses will be reimbursed provided vouchers therefore, or other supporting information as the Company may
reasonably require, are presented to the Company. 
 h. Fees and Expenses. The Company shall pay the reasonable fees
and expenses of Greenbaum, Rowe, Smith & Davis LLP, the Executive’s legal counsel, in connection with this Agreement, in an amount not to exceed $2,500 in the aggregate. 

4. Termination 
 a.
Rights and Duties. The Executive is an employee “at will.” Accordingly, the Company or the Executive may terminate his employment, at any time for any lawful reason, or no reason. The Executive and the Company agree that, without
modifying or altering the Executive’s “at will” status, each will provide the other with at least thirty (30) days’ prior 

  
 3 

 
written notice of termination of the Executive’s employment with the Company. If the Executive gives notice of termination, except in the case of a termination by the Executive for
“good reason” as set forth below, such notice will be deemed a voluntary resignation by the Executive and the Company, in its sole discretion, may elect to relieve the Executive of any obligation to perform duties during the notice
period, waive the notice period and immediately accept termination of the Executive’s employment, without changing the status of such termination as a voluntary resignation by the Executive. Should the Company in the event of a voluntary
resignation decide to relieve the Executive of any obligation to perform duties during the notice period, waive the notice period and immediately accept termination of the Executive’s employment, it shall nonetheless continue his compensation
and benefits for the term of the notice period, except that no bonus shall be earned or awarded during and after the notice period. 

b. Termination for “good reason.” The Executive may terminate his employment at any time for “good reason.”
“Good Reason” shall comport with the requirements of Regulation §1.409A-1(n)(ii) and shall mean: 
 i.
A substantial reduction in the Executive’s duties or responsibilities or a material change in his reporting responsibilities or title; 

ii. A substantial reduction by the Company in his annual compensation then in effect, except those changes generally affecting
the members of the Company’s management; 
 iii. A substantial adverse change or reduction in the Executive’s
participation in benefits under any benefit plan of the Company, including this Agreement, except those changes generally affecting the members of the Company’s management, provided that such change or reduction is within the purview of
Regulation §1.409A-1(n)(ii)(6). 
 iv. A requirement that the Executive be based more than 50 miles from the offices at
which he was principally employed immediately prior to the date of this Agreement. 
 c. Termination by the Company for Cause.
The Company may terminate the Executive’s employment at any time for “cause.” “Cause” shall mean: 

i. Executive’s commission of an act of fraud or dishonesty which may or does adversely affect the Company; 

ii. The Executive’s conviction or plea of guilty or nolo contendere to or engaging in any felony or crime involving
moral turpitude, fraud, misrepresentation or other crime and/or indictment for a crime that, in the reasonable opinion of the Company, affects the Executive’s ability to perform the duties set forth in this Agreement and/or reflects negatively
upon the Company; 
 iii. Unauthorized disclosure by the Executive of the Company’s Proprietary Information, as defined
in the Employee Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement which results or could have been reasonably foreseen to result, in a material financial loss to the Company. 

  
 4 

 iv. The Executive’s failure (which shall not include any disability as
defined below) or refusal to perform the duties and responsibilities of his employment and/or to follow the policies and procedures of the Company, including without limitation the failure or refusal to carry out lawful instructions from the Board.
If such failure or refusal is reasonably possible of being cured in the opinion of the Company, then the Executive will be given thirty (30) days after written notice from the Company of such failure or refusal to cure. 

d. Termination in the event of death or disability. The Agreement shall terminate upon the Executive’s death or Disability and the
Executive’s employment with the Company shall thereupon terminate. For purposes of the Agreement, “Disability” is defined as any illness, injury, accident or condition of either a physical or psychological nature as a result of which
the Executive is unable to perform the essential functions of his duties and responsibilities hereunder for 90 days during any period of 365 consecutive calendar days or for any consecutive 90-day period. 

e. Effect of termination. 

i. If the Executive is terminated by the Company for Cause, the Executive will only be entitled to payment when due of any
unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment provided that no such payment is made after March 15 of the calendar year following the Executive’s entitlement to such payment. 

ii. If the Executive is terminated by the Company other than for Cause or due to the Executive’s Disability, as defined
above (either of which will be deemed an involuntary termination), or the Executive terminates for Good Reason as defined in 4b hereof, the Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and
vacation days accrued prior to termination of employment provided that no such payment is made after March 15 of the calendar year following the Executive’s entitlement to such payment and, in exchange for the Executive’s execution of
a separation agreement and general release provided by the Company, the following: 
 a) Continuation of the Executive’s
compensation for six (6) months commencing on the Company’s next regularly scheduled payroll following the 10th day after the Executive provides to the Company an executed separation agreement and general release in a form acceptable to
the Company but which is generally consistent with the form of separation agreement and general release used by the Company for such purposes; and 

b) The Executive shall be eligible to continue health benefits pursuant to COBRA or the appropriate state equivalent. If the
Executive is eligible for and elects continuation of such coverage during the permissible time frame, the Company will pay the premiums for such group health insurance coverage for the shorter of (i) six (6) months or (ii) until the
Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of such group health insurance coverage. 

  
 5 

 iii. In the event of a termination by the Executive for Good Reason, the
Executive shall be entitled to the separation compensation and benefits set forth in paragraph 4.e.ii. 
 iv. If the
Agreement is terminated because of the Executive’s death, the Company shall pay to the estate of the Executive the salary and benefits which would otherwise have been payable to the Executive up to the date of termination of his employment
because of death, provided that no such payment is made after March 15 of the calendar year following the Executive’s entitlement to such payment. 

v. In the event a Change of Control (as defined below) occurs and, if within one (1) year thereafter, the Executive’s
employment is terminated as an involuntary termination by the Company for a reason other than for Cause, or by the Executive for Good Reason, then the Company shall pay to the Executive (as severance pay) a lump sum equal to one (1) year of his
then current base salary, less applicable withholdings, within thirty (30) days after the Executive has provided to the Company an executed separation agreement and general release in a form acceptable to the Company, which agreement and
release shall be delivered no later than thirty (30) days after such termination of employment. 
 For purposes of this Agreement,
“Change of Control” means (A) the occurrence of a merger or consolidation of the Company whether or not approved by the Board of Directors, other than (i) a merger or consolidation which would result in the voting securities of
the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power
represented by the voting securities of the Company or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation which is in effect a financing transaction
for the Company, including, but not limited to, a reverse merger of the Company into a publicly traded “shell” company, or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets, provided that, in any case, “Change in Control” shall be in accordance with Regulation §1.409A-3(i)(5)(v). 

5. Nondisclosure, Noncompetition, Nonsolicitation and Inventions: As a condition of the Executive’s employment by the
Company and the payment of compensation and receipt of benefits referred to above, the Executive agrees to execute the attached standard Employee Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement, in the form attached hereto as
Exhibit A. The Executive acknowledges that the Company would not offer him employment or provide compensation and/or benefits set forth above if he was not willing to be bound by the terms of such Agreement. 

  
 6 

 6. Notice. 

a. To the Company. The Executive will send all communications to the Company in writing, addressed as follows (or in any other manner
the Company notifies him to use): 
  

			
		  	 James C. Jenson, Ph.D.
 President and CEO

Dicerna Pharmaceuticals, Inc.
 790 Memorial Drive

Suite 104
 Cambridge, MA 02139

		
	With a copy to:	  	 Andrew J. Merken, Esq.
 Burns & Levinson,
LLP
 125 Summer Street
 Boston, MA 02110

 b. To the Executive. All communications from the Company to the Executive relating to this Agreement
shall be sent to the Executive in writing, addressed as follows (or in any other manner he notifies the Company to use): 
  

			
		  	 Bob D. Brown
 54 Leprechaun Drive

Millington, NJ 07946

		
	With a copy to:	  	 Thomas C. Senter, Esq.
 Greenbaum, Rowe,
Smith & Davis LLP
 Metro Corporate Campus One
 P.O. Box
5600
 Woodbridge, NJ 07095-0988

 c. Time Notice Deemed Given. Notice shall be deemed to have been given when delivered or, if earlier
(1) three business days after mailing by United States certified or registered mail, return receipt requested, postage prepaid, or (2) faxed with confirmation of delivery, in either case, addressed as required in this section. 

7. Amendment. No provisions of this Agreement may be modified, waived, or discharged except by a written document signed by a Company
officer duly authorized by the Board and the Executive. A waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at any other time in the future. 

8. Choice of Law. The validity, interpretation, construction, and performance of this Agreement shall be governed by the laws of the
Commonwealth of Massachusetts without regard to its conflicts of laws principles, except to the extent that federal law preempts such law. 

9. Successors. This Agreement shall be binding upon, and shall inure to the benefit of, the Executive and his estate, but the Executive
may not assign or pledge this Agreement or 

  
 7 

 
any rights arising under it. Without the Executive’s consent, the Company may assign this Agreement to any affiliate or to a successor to substantially all the business and assets of the
Company. 
 10. Taxes. The Company shall withhold taxes from payments it makes pursuant to this Agreement as it reasonably determines
to be required by applicable law. 
 11. Validity. The invalidity or unenforceability of any provision of this Agreement shall not
affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 
 12.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument. 

13. Entire Agreement; Prior Agreements. This Agreement, together with any other agreement described in this Agreement, constitutes the
entire agreement among the parties with respect to the subject matter hereof and, unless otherwise provided herein, supersedes all prior agreements or understandings written or oral in respect thereof. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

							
	Date: May 1, 2008	 		 	DICERNA PHARMACEUTICALS, INC.
			
		 		 	 /s/ James C. Jenson

		 		 	By:	 	James C. Jenson
		 		 	Its:	 	President and CEO
			
	Date: May     , 2008	 		 	BOB D. BROWN
			
		 		 	  

		 		 	Bob D. Brown

  
 9 

							
	Date: May     , 2008	 		 	DICERNA PHARMACEUTICALS, INC.
			
		 		 	  

		 		 	By:	 	James C. Jenson
		 		 	Its:	 	President and CEO
			
	Date: May 2, 2008	 		 	BOB D. BROWN
			
		 		 	 /s/ Bob D. Brown

		 		 	Bob D. Brown

  
 10 

 EXHIBIT A 

NONDISCLOSURE, NONCOMPETITION AND ASSIGNMENT AGREEMENT 

This Nondisclosure, Noncompetition and Assignment Agreement (the “Agreement”) is made by and between Dicerna Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and Bob D. Brown (the “Employee”), as of May 1, 2008. 
 The Employee
acknowledges that his/her employment or the continuance of that employment with the Company is contingent upon his/her agreement to sign and adhere to the provisions of this Agreement. In consideration of the employment or continued employment of
the Employee by the Company, the Employee and the Company agree as follows: 
 1. Day to Devote Efforts. The Employee understands
that his/her employment with the Company requires his/her undivided attention and effort during normal business hours and excluding periods of vacation and sick leave to which he/she is entitled. As a result, except as otherwise provided in
Section 2 of Employee’s Employment Agreement with the Company dated May 1, 2008, during his/her employment with the Company, he/she shall not engage in any other employment, occupation, consulting or other activity that conflicts with
his/her obligations to the Company, whether directly related to the business in which the Company is involved during the term of his/her employment with the Company or otherwise. For the avoidance of doubt, the Employee may engage in charitable,
civic and educational activities and community affairs, provided that any such activities and affairs do not, in the aggregate, materially interfere with the proper performance of the Employee’s duties and responsibilities to the
Company. 
 2. Noncompetition. The Employee recognizes and agrees that the Company will suffer irreparable harm in the event that the
Employee enters into competition with the Company, either during or following the Employee’s employment with the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of two (2) years
following the termination or cessation of such employment (the “Restricted Period”), regardless of the reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer,
lender or stockholder, or in any other capacity whatsoever, of any entity, (a) accept employment with any business or entity that is in competition with the products or services being conceived, designed, created, developed, manufactured,
marketed, distributed or sold by the Company, (b) engage in or undertake any business operations of conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering (or assisting any other person in
conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering) products or services that are in competition with the products or services being conceived, designed, created, developed, manufactured,
marketed, distributed, sold or rendered by the Company or (c) invest in or assist in any manner any business which directly or indirectly competes with the business or future business plans of the Company, except that he/she may own up to one
percent (1%) of the outstanding securities of any corporation having a class of equity securities actively traded on a national securities exchange or on the NASDAQ Stock Market. A business or entity shall be deemed to be in competition with
the products or services being conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company if it is in the business of development, manufacture, license, sale and

  
 11 

 
distribution of Dicer-substrate based therapeutic and diagnostic products (including, but not limited to, Dicector RNA interference technology and DsiRNA technology). The geographic scope of this
Section 2 shall extend to anywhere the Company is doing business, has done business or intends to do business. The Employee acknowledges and agrees that if he/she violates any of the provisions of this Section 2, the running of the
Restricted Period will be extended by the time during which he/she engages in such violation(s). 
 3. Nonsolicitation of Customers.
The Employee recognizes and agrees that the clients, customers and accounts of the Company, which the Company now or hereafter services during the Employee’s employment with the Company, and all prospective clients, customers and accounts from
whom the Employee has solicited business while in the employ of the Company, shall be solely the clients, customers and accounts of the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of
two (2) years following the termination or cessation of such employment, regardless of the reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or
stockholder, or in any other capacity whatsoever, of any entity, solicit, divert or take away, attempt to divert or to take away, any client, customer or account of the Company, or any potential client, customer or account of the Company which were
contacted, solicited or served by the Employee while employed by the Company or about whom the Employee obtained or became familiar with through Confidential Information (as defined in Section 5). The geographic scope of this Section 3
shall extend to anywhere the Company is doing business, has done business or intends to do business. 
 4. Nonsolicitation of
Employees. The Employee recognizes and agrees that the Company has invested substantial resources and effort in assembling its present staff and personnel. Therefore, the Employee agrees that while the Employee is employed by the Company and for
a period of two (2) years following the termination or cessation of such employment, regardless of the reasons, the Employee shall not, directly or indirectly: (i) recruit, solicit or hire any employee of the Company; or (ii) induce
or attempt to induce any employee of the Company to terminate his/her employment with, or otherwise cease his/her relationship or engagement with, the Company. 

5. Nondisclosure. The Employee agrees that all Confidential Information (as defined below), whether or not disclosed orally or in
writing, is and shall be the exclusive property of the Company. The Employee shall not at any time, whether during or after the termination or cessation of his/her employment, without written authorization of the Chief Executive Officer of the
Company, unless and until the Confidential Information has become public knowledge without fault by the Employee, (a) reveal any Confidential Information to any person or entity, except to employees of the Company who need to know such
Confidential Information for the purposes of their employment, (b) use or attempt to use any Confidential Information for any purposes (other than in the ordinary course of performing his/her duties as an employee of the Company), or
(c) use any Confidential Information in any manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. The term “Confidential Information” shall include any
information concerning the organization, business, business relationships or finances of the Company or of any third party which the Company is under an obligation to keep confidential or that is maintained by the Company as confidential. Such
Confidential Information shall include, but is not limited to, 

  
 12 

 
trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, specifications, blueprints, engineering data, software
programs, works of authorship, clinical testing programs, marketing material, customer lists, customer information, financial information, pricing information, personnel information, business plans or strategy, projects, plans and proposals. 

6. Company Property. 
 a.
The Employee agrees that Company Property (as defined below) shall be and is the exclusive property of the Company to be used by the Employee only in the performance of his/her duties for the Company and further agrees that during his/her employment
with the Company, or after the termination or cessation of such employment, he/she shall not make, use or permit to be used any Company Property otherwise than for the benefit of the Company. All such Company Property or copies thereof and all
tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) upon the termination or cessation of the Employee’s employment.
After such delivery, the Employee shall not retain any such Company Property or copies thereof or any other tangible property. The term “Company Property” shall include all files, letters, notes, memoranda, reports, lists, records,
drawings, sketches, laboratory notebooks, specifications, software programs, software code, data, computers, cellular telephones, pagers, credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any
form, whether written, photographic, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs and any other Company property in
Employee’s possession, custody or control. 
 b. The Employee agrees that his/her obligation not to disclose or to use information and
materials of the types set forth in Section 6(a) above, and his/her obligation to return materials and tangible property, set forth in Section 6(a) above, also extends to such types of information, materials and tangible property of
clients, customers and accounts of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee. 

7. Assignment of Developments. 

a. If at any time or times during Employee’s employment with the Company, he/she did or shall (either alone or with others) make,
conceive, create, discover, invent or reduce to practice, whether or not during normal working hours or on the premises of the Company, any Development that (i) relates to the business of the Company or any customer of or supplier to the
Company or any of the products or services being developed, manufactured or sold by the Company or which may be used in relation therewith; (ii) results from tasks assigned to the Employee by the Company; or (iii) results from the use of
premises or personal property (whether tangible or intangible) owned, leased or contracted for or by the Company, then all such Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and
its assigns, as works made for hire or otherwise. The term “Development” shall mean any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data,

  
 13 

 
technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes). The
Employee shall fully and promptly disclose to the Company (or any persons designated by it) each such Development. To the extent not already owned by the Company, the Employee agrees to assign and does hereby assign to the Company (or any person or
entity designated by the Company) all his/her right, title and interest (including, but not limited to, rights to inventions, patentable subject matter, copyrights and trademarks) in and to the Developments and all benefits and/or rights resulting
therefrom to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary plans and models) to the
Company. The Employee also hereby waives all claims to moral rights in any Developments. 
 b. Excluded Developments. This
Section 7 shall not apply to Developments the Employee created while employed by the Company about which Employee can prove that: (i) it was developed entirely on Employee’ s own time and effort; (ii) no equipment, supplies,
facilities, intellectual property, including trademarks, patents, copyrights and/or trade secrets or confidential and/or proprietary information of the Company and/or its officers, managers, employees, suppliers, customers or partners was used in
its development or was incorporated therein; (iii) it does not relate to or arise out of the Company’s actual and/or anticipated business activities; and (iv) it does not result from any work performed by Employee for the Company
within the scope of his employment or any other relationship with the Company. 
 8. Further Assurances. The Employee agrees to
cooperate fully with the Company, both during and after his/her employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and
foreign countries) relating to Developments. The Employee shall, during his/her employment and at any time thereafter, at the request and cost of the Company, promptly sign, execute, make and do all such deeds, documents, acts and things as the
Company and its duly authorized officers may reasonably require: 
 a. to apply for, obtain, register and vest in the name of the Company
alone (unless the Company otherwise directs) patents, copyrights, trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to renew and restore the same; and 

b. to defend any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or other proceeding,
petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 
 The Employee further agrees that if the
Company is unable, after reasonable effort, to secure the Employee’s signature on any such papers, application for patent, copyright, trademark or other analogous protection, or other documents regarding any legal protection relating to a
Development, whether because of the Employee’s physical or mental incapacity or for any other reason whatsoever, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the
Employee’s agent and attorney-in-fact, to act for and on his/her behalf and stead to execute and file any such papers, application or applications or other documents and to do any and all other lawfully permitted acts to further the prosecution
and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by the Employee. 

  
 14 

 9. Employment At Will. The Employee understands that this Agreement does not constitute an
implied or written employment contract and that his/her employment with the Company is on an “at-will” basis. Accordingly, the Employee understands that either the Company or the Employee may terminate Employee’s employment at any
time, for any or no reason, with or without prior notice, except as otherwise provided for in the Employee’s Employment Agreement with the Company dated May 1, 2008. 

10. Severability. The Employee hereby agrees that each provision and the subparts of each provision herein shall be treated as separate
and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if one or more of the provisions contained in this Agreement shall for any reason
be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be
enforceable to the maximum extent compatible with the applicable law as it shall then appear. The Employee hereby further agrees that the language of all parts of this Agreement shall in all cases be construed as a whole according to its fair
meaning and not strictly for or against either of the parties. 
 11. Amendments; Waiver. Any amendment to or modification of this
Agreement, or any waiver of any provision hereof, shall be in writing and signed by the Company. No delay or omission by the Company in exercising any right under this Agreement or any waiver by the Company of a breach of any provision of this
Agreement shall not operate or be construed as a waiver of that right or any subsequent breach of such provision or any other provision hereof. 

12. Survival. This Agreement shall be effective as of the date entered below. The Employee’s obligations under this Agreement
shall survive the termination or cessation of his/her employment regardless of the manner of such termination or cessation and shall be binding upon his/her heirs, executors, administrators and legal representatives. 

13. Assignment. The term “Company” shall include Dicerna Pharmaceuticals, Inc. and any of its subsidiaries, divisions, or
affiliates. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said successors or assigns. The Employee may not
assign this Agreement. 
 14. Representations. 

a. The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms
of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company or to refrain from competing, directly or
indirectly, with the business of such previous employer or any other party. The Employee further represents that his/her performance of all the terms of 

  
 15 

 
this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by the Employee in confidence
or in trust prior to his/her employment with the Company, and the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others. The
Employee further represents that he/she has returned all property and confidential information belonging to all prior employers. To the extent that Employee has retained any non-confidential and non-proprietary materials and documents of a prior
employer, such materials and documents have been disclosed in writing to the Company. 
 b. The Employee hereby represents that his/her
employment with the Company, the execution of this Agreement and his/her performance of all of the terms of this Agreement do not and will not conflict with or breach the terms of any other agreement by which the Employee is bound (including, but
not limited to, to keeping in confidence proprietary information acquired by the Employee in confidence or in trust prior to his/her employment by the Company). The Employee further represents that he/she shall not enter into any agreement, either
written or oral, in conflict herewith. 
 c. The restrictions contained in this Agreement are necessary for the protection of the business
and goodwill of the Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement by him/her is likely to cause substantial and irreparable damage to the Company and that in the
event of such breach the Company shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation of the Employee’s obligations hereunder. The Company
may apply for such injunctive relief in any court of competent jurisdiction without the necessity of posting any bond or other security. 

15. Governing Law; Forum Selection Clause. This Agreement and any claims arising out of this Agreement (or any other claims arising out
of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without application of the conflict of laws principles thereof. Any claims or legal actions by one party
against the other shall be commenced and maintained in any state or federal court located in the Commonwealth of Massachusetts, and the parties hereby submit to the jurisdiction and venue of any such court. 

16. Entire Agreement. This Agreement sets forth the complete, sole and entire agreement between the parties on the subject matter
herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into, discussed or considered by the parties. The Employee agrees that any change or changes in
his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

  
 16 

 THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND
AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. 
 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as of the
1st day of May, 2008. 
  

			
	Signature:	 	  

		
	Name (Please Print):	 	  

		
	Address:	 	  

	  

	  

  

			
	 ACKNOWLEDGED BY:
  

DICERNA PHARMACEUTICALS, INC.

		
	By:	 	 /s/ James C. Jenson

		
	Name:	 	 James C. Jenson

		
	Title:	 	 President and CEO

  
 17 

 previously entered into, discussed or considered by the parties. The Employee agrees that any change or changes
in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as of the 2nd day of May 2008. 
  

			
	Signature:	 	 /s/ Bob D. Brown

		
	Name (Please Print):	 	 Bob D. Brown

		
	Address:	 	  

	  

	  

 

			
	 ACKNOWLEDGED BY:

 
 DICERNA PHARMACEUTICALS, INC.

		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

  
 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]